Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. NAMS
  6. >
  7. Valuation
stocks logo

NAMS Valuation

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D

NAMS Relative Valuation

NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAMS is overvalued; if below, it's undervalued.

Historical Valuation

NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 141.88 is considered Fairly compared with the five-year average of 3.35. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 4.35 to 80.98 according to relative valuation methord.
Relative Value
Fair Zone
4.35-80.98
Current Price:21.44
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.03
P/B
Median3y
3.26
Median5y
0.41
-5.65
FCF Yield
Median3y
-6.00
Median5y
-6.00

Competitors Valuation Multiple

The average P/S ratio for NAMS's competitors is 38.35, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 141.88, which is 269.97% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

People Also Watch

FAQ

arrow icon

Is NewAmsterdam Pharma Company NV (NAMS) currently overvalued or undervalued?

NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 141.88 is considered Fairly compared with the five-year average of 3.35. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 4.35 to 80.98 according to relative valuation methord.
arrow icon

What is NewAmsterdam Pharma Company NV (NAMS) fair value?

NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 4.35 to 80.98 according to relative valuation methord.
arrow icon

How does NAMS's valuation metrics compare to the industry average?

The average P/S ratio for NAMS's competitors is 38.35, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 141.88, which is 269.97% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.
arrow icon

What is the current P/B ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?

As of Jul 18 2025, NewAmsterdam Pharma Company NV (NAMS) has a P/B ratio of 3.03. This indicates that the market values NAMS at 3.03 times its book value.
arrow icon

What is the current FCF Yield for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?

As of Jul 18 2025, NewAmsterdam Pharma Company NV (NAMS) has a FCF Yield of -5.65%. This means that for every dollar of NewAmsterdam Pharma Company NV’s market capitalization, the company generates -5.65 cents in free cash flow.
arrow icon

What is the current Forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?

As of Jul 18 2025, NewAmsterdam Pharma Company NV (NAMS) has a Forward P/E ratio of -10.49. This means the market is willing to pay $-10.49 for every dollar of NewAmsterdam Pharma Company NV’s expected earnings over the next 12 months.
arrow icon

What is the current Forward P/S ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?

As of Jul 18 2025, NewAmsterdam Pharma Company NV (NAMS) has a Forward P/S ratio of 141.88. This means the market is valuing NAMS at $141.88 for every dollar of expected revenue over the next 12 months.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free